Wall Street analysts expect Horizon Pharma PLC (NASDAQ:HZNP) to report $267.58 million in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Horizon Pharma’s earnings. The highest sales estimate is $268.91 million and the lowest is $266.25 million. Horizon Pharma reported sales of $310.35 million in the same quarter last year, which indicates a negative year over year growth rate of 13.8%. The business is scheduled to issue its next quarterly earnings report before the market opens on Wednesday, February 28th.
According to Zacks, analysts expect that Horizon Pharma will report full year sales of $267.58 million for the current fiscal year, with estimates ranging from $1.04 billion to $1.05 billion. For the next fiscal year, analysts forecast that the firm will report sales of $1.13 billion per share, with estimates ranging from $1.11 billion to $1.15 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Horizon Pharma.
A number of research analysts recently weighed in on the stock. ValuEngine cut shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Piper Jaffray Companies set a $18.00 target price on shares of Horizon Pharma and gave the company a “buy” rating in a research note on Sunday, October 15th. Cantor Fitzgerald set a $17.00 target price on shares of Horizon Pharma and gave the company a “buy” rating in a research note on Monday, January 8th. BidaskClub upgraded shares of Horizon Pharma from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. Finally, UBS Group set a $20.00 price target on shares of Horizon Pharma and gave the company a “buy” rating in a report on Thursday, November 30th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $19.25.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. UBS Asset Management Americas Inc. increased its holdings in Horizon Pharma by 11.6% in the 4th quarter. UBS Asset Management Americas Inc. now owns 104,024 shares of the biopharmaceutical company’s stock valued at $1,519,000 after acquiring an additional 10,780 shares during the last quarter. Capital Fund Management S.A. increased its holdings in Horizon Pharma by 56.7% in the 4th quarter. Capital Fund Management S.A. now owns 87,049 shares of the biopharmaceutical company’s stock valued at $1,271,000 after acquiring an additional 31,493 shares during the last quarter. State of Wisconsin Investment Board increased its holdings in Horizon Pharma by 28.9% in the 4th quarter. State of Wisconsin Investment Board now owns 163,700 shares of the biopharmaceutical company’s stock valued at $2,390,000 after acquiring an additional 36,700 shares during the last quarter. First Trust Advisors LP bought a new stake in Horizon Pharma in the 4th quarter valued at $689,000. Finally, Swiss National Bank increased its holdings in Horizon Pharma by 2.9% in the 4th quarter. Swiss National Bank now owns 278,156 shares of the biopharmaceutical company’s stock valued at $4,061,000 after acquiring an additional 7,800 shares during the last quarter. Institutional investors own 85.95% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Analysts Anticipate Horizon Pharma PLC (HZNP) Will Post Quarterly Sales of $267.58 Million” was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/10/analysts-anticipate-horizon-pharma-plc-hznp-will-post-quarterly-sales-of-267-58-million.html.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.